Finding broadly protective antibodies for Crimean‑Congo hemorrhagic fever
Isolation of broadly protective monoclonal antibodies for Crimean Congo Hemorrhagic Fever
Researchers are collecting blood from people who recovered from Crimean‑Congo hemorrhagic fever to find antibodies that could protect others from the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11143287 on NIH RePORTER |
What this research studies
If you join, researchers will build a group of about 120 people who recovered from CCHF and collect blood samples to look for protective antibodies. They will isolate a large panel of antibodies from those samples and pick the most promising candidates for further study. The best antibodies will be tested in lab and mouse models to see if they protect against different virus strains. The team will also map exactly where the leading antibodies bind on the virus to help guide future treatments or vaccines.
Who could benefit from this research
Good fit: Ideal candidates are people who previously had and recovered from laboratory‑confirmed CCHF and are willing to provide blood samples, particularly survivors in the study area (Turkey).
Not a fit: People who have never had CCHF, are currently infected, or are unable/unwilling to give blood are unlikely to be eligible or receive direct benefit from participation.
Why it matters
Potential benefit: This work could lead to antibody-based treatments or help design vaccines that prevent or treat CCHF in the future.
How similar studies have performed: Similar approaches have identified protective monoclonal antibodies in animals and some human antibodies have been isolated, but broadly cross‑protective human antibodies against multiple CCHFV strains remain limited.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Sajadi, Mohammad Mohseni — University of Maryland Baltimore
- Study coordinator: Sajadi, Mohammad Mohseni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.